Editing Survival Statistics (section)

== What Role Does Cell Type Play in Prognosis? ==

Mesothelioma cell type (histology) represents another critical prognostic factor that significantly influences treatment options and survival expectations.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide/ Mesothelioma Cancer Guide], Danziger & De Llano</ref>

'''Epithelioid Mesothelioma''' accounts for 50-70% of cases and carries the most favorable prognosis.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/epithelioid/ Epithelial Mesothelioma], Mesothelioma Attorney</ref> Median survival ranges from 14-18 months, with approximately 14% 5-year survival. This cell type responds best to chemotherapy, immunotherapy, and surgical interventions.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/types/epithelial/ Epithelioid Mesothelioma], Mesothelioma Lawyer Center</ref>

'''Sarcomatoid Mesothelioma''' represents 10-20% of cases and demonstrates the poorest outcomes, with median survival of only 4-8 months and approximately 4% 5-year survival.<ref>[https://dandell.com/lawyers/paul-danziger/ Paul Danziger], Danziger & De Llano</ref> Historically resistant to chemotherapy, this aggressive subtype now shows dramatically improved outcomes with immunotherapy. The CheckMate 743 trial demonstrated median survival of 18.1 months versus 8.8 months with chemotherapy for non-epithelioid disease—effectively doubling survival.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/sarcomatoid/ Sarcomatoid Mesothelioma Guide], Mesothelioma Attorney</ref>

'''Biphasic Mesothelioma''' contains both epithelioid and sarcomatoid cells, with prognosis depending on the ratio of each cell type.<ref>[https://dandell.com/lawyers/rod-de-llano/ Rod de Llano], Danziger & De Llano</ref> Tumors with predominantly epithelioid features behave more favorably than those with dominant sarcomatoid components.

{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✓ Immunotherapy Breakthrough for Non-Epithelioid Disease''' The 2025 ASCO Guidelines now recommend nivolumab plus ipilimumab as the preferred first-line treatment for non-epithelioid mesothelioma based on the dramatic survival benefit demonstrated in CheckMate 743 (hazard ratio 0.46).
|}